TY - JOUR
T1 - Central nervous system drug evaluation using positron emission tomography
AU - Sekine, Mizuho
AU - Maeda, Jun
AU - Shimada, Hitoshi
AU - Nogami, Tsuyoshi
AU - Arakawa, Ryosuke
AU - Takano, Harumasa
AU - Higuchi, Makoto
AU - Ito, Hiroshi
AU - Okubo, Yoshiro
AU - Suhara, Tetsuya
PY - 2011/4
Y1 - 2011/4
N2 - In conventional pharmacological research in the field of mental disorders, pharmacological effect and dose have been estimated by ethological approach and in vitro data of affinity to the site of action. In addition, the frequency of administration has been estimated from drug kinetics in blood. However, there is a problem regarding an objective index of drug effects in the living body. Furthermore, the possibility that the concentration of drug in blood does not necessarily reflect the drug kinetics in target organs has been pointed out. Positron emission tomography (PET) techniques have made progress for more than 20 years, and made it possible to measure the distribution and kinetics of small molecule components in living brain. In this article, we focused on rational drug dosing using receptor occupancy and proof-of-concept of drugs in the drug development process using PET. Copyright
AB - In conventional pharmacological research in the field of mental disorders, pharmacological effect and dose have been estimated by ethological approach and in vitro data of affinity to the site of action. In addition, the frequency of administration has been estimated from drug kinetics in blood. However, there is a problem regarding an objective index of drug effects in the living body. Furthermore, the possibility that the concentration of drug in blood does not necessarily reflect the drug kinetics in target organs has been pointed out. Positron emission tomography (PET) techniques have made progress for more than 20 years, and made it possible to measure the distribution and kinetics of small molecule components in living brain. In this article, we focused on rational drug dosing using receptor occupancy and proof-of-concept of drugs in the drug development process using PET. Copyright
UR - http://www.scopus.com/inward/record.url?scp=79955763846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955763846&partnerID=8YFLogxK
U2 - 10.9758/cpn.2011.9.1.9
DO - 10.9758/cpn.2011.9.1.9
M3 - Review article
AN - SCOPUS:79955763846
SN - 1738-1088
VL - 9
SP - 9
EP - 16
JO - Clinical Psychopharmacology and Neuroscience
JF - Clinical Psychopharmacology and Neuroscience
IS - 1
ER -
